Posted by Michael Wonder on 24 May 2022
ImmunoGen announces acceptance of biologics license application for mirvetuximab soravtansine in ovarian cancer by US Food and Drug Administration with priority review
23 May 2022 - PDUFA date is 28 November 2022.
ImmunoGen today announced that the US FDA has accepted and filed the biologics license application for mirvetuximab soravtansine monotherapy in patients with folate receptor alfa high platinum-resistant ovarian cancer who have been previously treated with 1 to 3 prior systemic treatments.
